<DOC>
	<DOCNO>NCT01196897</DOCNO>
	<brief_summary>This study evaluate next generation WATCHMAN Left Atrial Appendage ( LAA ) Closure Device implant patient non-valvular atrial fibrillation ( AF ) CHADS2 stroke risk stratification score 1 great . This prospective , non-randomized study evaluate initial use next generation WATCHMAN Device .</brief_summary>
	<brief_title>Evaluation Next Generation WATCHMAN LAA Closure Technology Non-Valvular AF Patients ( EVOLVE )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Key Paroxysmal , persistent , permanent nonvalvular atrial fibrillation Eligible longterm Warfarin therapy ; Eligible come Warfarin therapy LAA seal Calculated CHADS2 score 1 great Key New York Heart Association Class IV Congestive Heart Failure Recent MI ( within 3 month ) ASD and/or atrial septal repair closure device Resting heart rate &gt; 110 bpm Has implant mechanical valve prosthesis Left atrial appendage obliterate Has undergone heart transplantation Has symptomatic carotid disease Contraindicated aspirin LVEF &lt; 30 % Cardiac Tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Coumadin</keyword>
	<keyword>TIA</keyword>
	<keyword>Trans Ischemic Attack</keyword>
</DOC>